Loading...
XNAS
TXMD
Market cap23mUSD
Oct 08, Last price  
2.01USD
1D
0.50%
1Q
0.50%
Jan 2017
-99.30%
IPO
-96.78%
Name

TherapeuticsMD Inc

Chart & performance

D1W1MN
XNAS:TXMD chart
P/E
—
P/S
7.70
EPS
—
Div yield, %
—
Shrs. gr., 5y
15.98%
Rev. gr., 5y
-45.84%
Revenues
3m
+71.61%
1,005,2740010,56948,2172,088,1773,818,0138,775,59815,026,21920,142,89819,356,45016,777,71316,099,46049,647,00064,872,0002,573,00069,963,0001,302,0001,761,0003,022,000
Net income
-569k
L-73.91%
373,015170,542-395,553-1,654,541-695,375-12,913,365-35,120,235-28,419,313-54,217,210-85,077,024-89,875,459-76,925,380-132,617,160-176,145,000-183,524,000-172,415,000111,997,000-10,278,000-2,181,000-569,000
CFO
2m
+231.15%
329,840344,098-133,003-417,338836,832-4,966,596-12,737,326-20,768,069-45,520,996-79,044,119-69,142,333-76,155,614-106,811,781-165,697,595-159,471,000-147,811,000-4,078,000-48,141,000732,0002,424,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.

Key people

Robert G. Finizio
Chief Executive Officer and Director · since 2012
Brian A. Bernick
Co-Founder · since 2020
Daniel A. Cartwright
Chief Financial Officer and Treasurer · since 2015
Joel S. Krasnow
Chief Scientific Officer, Head - Regulatory Department · since 2013
John Knighton
Chief Compliance Officer · since 2018
Michael Donegan
Vice President - Finance · since 2013
Independent Director · since 2016
Jules A. Musing
Independent Director · since 2017
Independent Director · since 2015
Independent Chairman of the Board · since 2012
IPO date
Jan 31, 2001
Employees
1
Domiciled in
US
Incorporated in
US
Legal address
c/o Paracorp Incorporated, 318 N Carson St #208
Carson City, NV 89701
US
Headquarters
Suite 320, 951 Broken Sound Parkway North West
Boca Raton, FL 33487
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT